Clearpoint Neuro Stock Today

CLPT Stock  USD 16.72  0.34  2.08%   

Performance

OK

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
Clearpoint Neuro is selling for under 16.72 as of the 26th of February 2025; that is 2.08 percent increase since the beginning of the trading day. The stock's last reported lowest price was 15.28. Clearpoint Neuro has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
12th of February 2020
Category
Healthcare
Classification
Health Care
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Clearpoint Neuro operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 27.58 M outstanding shares of which 653.42 K shares are currently shorted by private and institutional investors with about 2.77 trading days to cover. More on Clearpoint Neuro

Moving against Clearpoint Stock

  0.78TFX Teleflex IncorporatedPairCorr
  0.63UNH UnitedHealth GroupPairCorr
  0.62EDIT Editas Medicine Earnings Call TodayPairCorr
  0.6CI Cigna CorpPairCorr
  0.55COO Cooper Companies, Earnings Call TodayPairCorr
  0.46DHR DanaherPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Clearpoint Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentJoseph Burnett
Old NameCollplant Holdings Ltd
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.690.65
Notably Up
Slightly volatile
Gross Profit Margin0.750.65
Fairly Up
Slightly volatile
Total Current Liabilities4.7 M6.7 M
Way Down
Slightly volatile
Non Current Liabilities Total9.6 M16.2 M
Way Down
Slightly volatile
Total Assets51.5 M49.1 M
Sufficiently Up
Slightly volatile
Total Current Assets43.7 M41.6 M
Sufficiently Up
Slightly volatile
Debt Levels
Clearpoint Neuro can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Clearpoint Neuro's financial leverage. It provides some insight into what part of Clearpoint Neuro's total assets is financed by creditors.
Liquidity
Clearpoint Neuro currently holds 13.94 M in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the company is not taking enough advantage from borrowing. Clearpoint Neuro has a current ratio of 10.12, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Clearpoint Neuro's use of debt, we should always consider it together with its cash and equity.

Other Non Cash Items

1.44 Million
Clearpoint Neuro (CLPT) is traded on NASDAQ Exchange in USA. It is located in 120 S. Sierra Avenue, Solana Beach, CA, United States, 92075 and employs 107 people. Clearpoint Neuro is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 461.22 M. Clearpoint Neuro conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 27.58 M outstanding shares of which 653.42 K shares are currently shorted by private and institutional investors with about 2.77 trading days to cover. Clearpoint Neuro currently holds about 45.14 M in cash with (13.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84.
Check Clearpoint Neuro Probability Of Bankruptcy
Ownership Allocation
Clearpoint Neuro holds a total of 27.58 Million outstanding shares. 30% of Clearpoint Neuro outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Clearpoint Ownership Details

Clearpoint Stock Institutional Holders

InstituionRecorded OnShares
Qube Research & Technologies2024-12-31
234.5 K
Jane Street Group Llc2024-12-31
222.3 K
Taylor Frigon Capital Management Llc2024-12-31
212.2 K
Conway Capital Management Inc2024-12-31
161.2 K
Lane Generational Llc2024-12-31
157.7 K
Parsons Capital Management Inc2024-12-31
141.6 K
Goldman Sachs Group Inc2024-12-31
130 K
Legato Capital Management Llc2024-12-31
122.1 K
State Street Corp2024-12-31
116.2 K
Vanguard Group Inc2024-12-31
1.2 M
Susquehanna International Group, Llp2024-12-31
509.2 K
View Clearpoint Neuro Diagnostics

Clearpoint Neuro Historical Income Statement

At this time, Clearpoint Neuro's Interest Income is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 457.6 K in 2025, despite the fact that Operating Income is likely to grow to (19.2 M). View More Fundamentals

Clearpoint Stock Against Markets

Clearpoint Neuro Corporate Management

Mazin SabraChief OfficerProfile
Danilo DAlessandroChief OfficerProfile
Ellisa JDGeneral SecretaryProfile
Ellisa CholapraneeGeneral SecretaryProfile
Jeremy StigallExecutive DeliveryProfile
Jacqueline KellerVice MarketingProfile

Additional Tools for Clearpoint Stock Analysis

When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.